SEC-sourced researchBeta
IDYA
IDEAYA Biosciences, Inc.
Company comparison ↗
Data passport
- CIK
- 0001676725
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Oct 6, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 23,385,000.0000 | Feb 17, 2026 |
| December 2024 | 7,000,000.0000 | Feb 17, 2026 |
| December 2025 | 218,710,000.0000 | Feb 17, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 218,710,000.0000 | -113,698,000.0000 | -71,098,000.0000 | 1,109,324,000.0000 | 86,390,000.0000 | Feb 17, 2026 |
| December 2024 | 7,000,000.0000 | -274,477,000.0000 | -247,584,000.0000 | 1,124,091,000.0000 | 64,944,000.0000 | Feb 17, 2026 |
| December 2023 | 23,385,000.0000 | -112,961,000.0000 | -115,224,000.0000 | — | — | Feb 17, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $218.71M | December 2025 | Feb 17, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $7M | December 2024 | Feb 17, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$113.7M | December 2025 | Feb 17, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$71.1M | December 2025 | Feb 17, 2026 | 10-K |
| Total assetsAssets | $1.11B | December 2025 | Feb 17, 2026 | 10-K |
| Total liabilitiesLiabilities | $86.39M | December 2025 | Feb 17, 2026 | 10-K |